After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
How this was made
The 30-second read
Why it matters
Traders can use the disclosed catalysts to frame near-term volatility and event risk, especially for AMLX’s scheduled Phase 3 topline and IVF’s earnings-driven repricing.
Market read
The article highlights immediate after-hours repricing tied to corporate actions, earnings, and scheduled clinical catalysts, offering actionable timing for short-horizon positioning.
What to watch
For PFSA and APLM, the article lacks key details (terms, financing structure, and cash runway). For AMLX, the magnitude of the move will hinge on endpoints and safety, which are not provided here.
Background
This is a multi-name after-hours gainers wrap covering reverse splits, Q2 earnings, an IPO debut, and pre-event positioning ahead of a Phase 3 topline.
Ticker impact
Profusa implemented a 1-for-4 reverse split, cutting shares outstanding and driving a large after-hours jump.
Likely choppy follow-through or mean reversion depending on continued after-hours bid.
The article discloses the exact split ratio and share-count reduction, but provides no new operating fundamentals beyond the split and prior option deal.
INVO Fertility reported Q2 results with revenue up 17% YoY and net income versus a prior-year loss, lifting after-hours gains.
Bias to continued strength into the next session if after-hours bid holds.
The article includes specific Q2 financial figures and quantifies the after-hours extension, indicating a fresh earnings-driven repricing.
Vogenx surged after its Nasdaq debut, with the IPO priced at $13 and after-hours shares up sharply.
High probability of volatility, with upside continuation possible but risk of rapid pullback.
The article provides IPO size/price and the after-hours move, but no new trial or regulatory data.
Amylyx shares rose ahead of Phase 3 LUCIDITY topline results for Avexitide, scheduled for August 18, 2026.
Pre-topline drift higher is possible, but expect sharp repricing at release.
The article states the exact upcoming topline timing and that the stock is already reacting in after-hours.
Apollomics gained in after-hours after announcing a $10 million private placement transaction last week.
Near-term trading likely driven by dilution interpretation and follow-on financing expectations.
The article discloses the private placement amount but not terms (price, structure), limiting conviction on direction.
YD Bio reported full-year 2025 results with revenue up 17% YoY but a wider net loss, and shares jumped after-hours.
Possible continued volatility; direction depends on whether investors focus on revenue growth versus loss expansion.
The article provides both revenue and net loss changes plus the after-hours move, but not guidance or cash runway details.
Genprex rose after-hours, citing its Roche Diagnostics collaboration to validate biomarkers for NSCLC trial patient selection.
Short-term upside bias, but likely capped until more clinical readouts.
The article includes the Roche collaboration and trial context, yet the move is not tied to new clinical results in this text.
Market effects
Biotech and healthcare names dominate the tape, reinforcing event-driven trading around reverse splits, earnings, IPO debuts, and Phase 3 toplines.
Primarily US-listed small/mid-cap biotech and healthcare, with after-hours liquidity effects likely concentrated in Nasdaq/US premarket flows.
Limited direct global macro linkage; effects are mostly company-specific within biotech risk appetite.
Counterpoint
Reverse splits and pre-topline runs can reverse quickly if the market interprets dilution or trial outcomes less favorably than expected.
Key entities
- companyProfusa Inc.
Implemented a 1-for-4 reverse stock split and saw a large after-hours move.
- companyINVO Fertility Inc.
Reported Q2 2026 results with revenue growth and net income improvement.
- companyAmylyx Pharmaceuticals Inc.
Phase 3 LUCIDITY topline results for Avexitide scheduled for August 18, 2026.
- companyVogenx Inc.
Nasdaq debut after IPO pricing, with strong after-hours gains.
- companyApollomics Inc.
Announced a $10 million private placement transaction.
